A Harvard Medical Perspective on the Peptide Boom

On September 1, 2026, the FDA published a coordinated set of warning letters targeting five online peptide vendors. The sweep signals that the agency is shifting from case-by-case enforcement to sector-wide scrutiny — and that a "research use only" disclaimer is no longer a regulatory shield. Here is what the letters actually say, which vendors and products were named, and what it means for labs sourcing peptides today.

Copper peptide serums have been a skincare staple for years, but a new trend has emerged: people are drawing GHK-Cu into syringes and injecting it at home in pursuit of firmer skin, thicker hair, and slower aging. Here's what the research actually supports, what remains unknown, and why sourcing quality matters for anyone studying this compound.

On September 1, 2026, Rep. Nancy Mace introduced the PEPTIDES for Veterans Act, a bill directing the Department of Veterans Affairs to formally study peptide-based therapies for veterans receiving VA care. Here's what the bill actually does, and doesn't do, for the research community.

Peptides like BPC-157, TB-500, MOTS-c, KPV, epitalon, and semax have become some of the most searched compounds in longevity and biohacking circles. Social media has fueled claims that they speed healing, improve sleep, build muscle, and boost energy. But according to cancer researchers, the evidence behind many of these claims is thin, and there's an open scientific question that gets far less attention than the hype: could some peptides affect cancer risk?

An Australian lab that now spends half its time analyzing peptides bought online has found that black-market vials of a popular weight-loss peptide are just as likely to be overdosed as underdosed. The results add a new dimension to the safety debate around unapproved peptides and underscore why verified sourcing matters.

Peptides are being marketed on TikTok as a shortcut to a younger, sharper-looking face. A pharmaceutical sciences researcher explains why the hype is running well ahead of the evidence, and why sourcing and safety data matter more than ever.

A new Tampa Bay Times report finds that peptides have become one of Florida's fastest-growing health trends, with social media influencers driving demand for compounds marketed to ease joint pain, speed weight loss, and improve sleep. Compounding pharmacists like Dr. David Pino say order volumes have surged, raising fresh questions about oversight, purity, and who's actually formulating what people are injecting.

President Trump has picked Dr. Heidi Overton, a physician and White House health policy aide, as his nominee to lead the FDA. If confirmed by the Senate, she would inherit one of the agency's most closely watched open questions: what happens next for peptides like BPC-157 and TB-500 after this summer's advisory panel vote.

Peptides are everywhere on social media, but most of the unapproved products behind the hype have never been checked for what's actually in the vial. A new public-health review breaks down the safety gaps regulators are racing to close, and why sourcing verification matters more than ever.